Clinical Trial - Trial jRCT2031230100
Access comprehensive clinical trial information for jRCT2031230100 through Pure Global AI's free database. This phase not specified trial is sponsored by Janssen Pharmaceutical K.K. and is currently Recruiting. The study focuses on Acute Coronary Syndrome.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Japan Registry Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
jRCT2031230100
Recruiting
Trial Details
Japan Registry Clinical Trial • jRCT2031230100
Untitled Trial
A Phase 3, Randomized, Double blind, Placebo controlled, Event driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome
(LIBREXIA ACS
)
Study Focus
Interventional
Sponsor & Location
Janssen Pharmaceutical K.K.
Argentina;Australia; Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Croatia;Czech;Denmark;Estoni
Timeline & Enrollment
N/A
N/A
N/A
ICD-10 Classifications
Acute myocardial infarction
Acute myocardial infarction, unspecified
Acute subendocardial myocardial infarction
Acute ischaemic heart disease, unspecified
Other acute ischaemic heart diseases
Data Source
Japan Registry Clinical Trial
jRCT2031230100
Non-Device Trial